Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Salestools Logo

Salestools

L'agent IA #1 pour les équipes de vente et Go-to-Market. Vendez plus, plus vite, avec moins d'effort.

Produit

  • Agents de vente IA
  • Données d'intention
  • Données technologiques
  • Suivi des visiteurs
  • Copilote
  • Vente sociale

Solutions

  • Service client
  • E-commerce
  • SaaS
  • Entreprise
  • Petite entreprise

Ressources

  • Le rapport
  • Documentation
  • Référence API
  • Centre d'aide
  • Blog
  • Études de cas
  • Webinaires

Entreprise

  • À propos
  • Carrières
  • Presse
  • Contact
  • Partenaires

Nos bureaux

  • New York, HQ
  • Bucarest, Laboratoire de recherche IA
  • Zug, Suisse

© 2025 Salestools. Tous droits réservés.

Conditions relatives aux données et sécuritéPolitique de confidentialitéConditions de service
Tous les systèmes opérationnels
Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Back to The Report
Biotech

Xaira Therapeutics

Xaira Therapeutics raises $1B Series A at $4B valuation

$1B
Total Raised
Series A
Latest Round
2023
Founded
100+
Employees
San Francisco, CA
Updated April 23, 2024
1 min read

Quick Facts

Valuation
$4B
Latest Round Size
$1B
Latest Round Date
April 2024

Xaira Therapeutics: Series A Funding Round

Xaira Therapeutics has successfully raised $1B in Series A funding, reaching a valuation of $4B.

Company Overview

AI-powered drug discovery platform

Funding Details

The Series A round was led by Foresite Capital, with participation from ARCH Venture Partners, NEA.

Company Information

  • Headquarters: San Francisco, CA
  • Founded: 2023
  • Employees: 100+
  • Category: Biotech

Investment

Xaira Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Foresite Capital: Verified investor in Series A
  • ARCH Venture Partners: Verified investor in Series A
  • NEA: Verified investor in Series A

Key Investors

Foresite Capital
Lead Investor
Verified investor in Series A
ARCH Venture Partners
Investor
Verified investor in Series A
NEA
Investor
Verified investor in Series A

Topics

verified(3079)real-funding(3079)san-francisco(299)xaira-therapeuticsbiotechseries-a

About the Author

Editorial Team
Editorial Team
Curated funding news from verified sources

Related Company Reports

Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology

Vir Biotechnology Raises $250M

Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$250M